Similar efficacy of lopinavir/ritonavir-containing regimens among clades B and F HIV-1-Infected individuals in Brazil.
Diaz
Ricardo Sobhie
RS
Vasconcelos
Lucy
L
Hayden
Ricardo L
RL
Tenore
Simone
S
Turcato
Gilberto
G
Palácios
Ricardo
R
Sucupira
Maria C
MC
D001938:Brazil; D018791:CD4 Lymphocyte Count; D004338:Drug Combinations; D018432:Drug Resistance, Multiple / Q000235:genetics; D024882:Drug Resistance, Viral / Q000235:genetics; D005838:Genotype; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D061466:Lopinavir; D009154:Mutation; D011446:Prospective Studies; D011744:Pyrimidinones / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood / Q000235:genetics; D019438:Ritonavir / Q000627:therapeutic use*; D013995:Time; D013997:Time Factors; D016896:Treatment Outcome
D004338:Drug Combinations; D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D012367:RNA, Viral; D061466:Lopinavir; D019438:Ritonavir